The week at Retraction Watch featured the retraction of a much-discussed paper on using blockchain to prevent scientific misconduct, and a researcher who lost nine studies at once from a single journal. Here’s what was happening elsewhere:Ollie’s on the editorial board of seven journals, maybe because she always obeys a “sit” command. She’s a dog, and the heart of a journal sting.
ood guys finish last, the saying goes. But here’s a story that should offer hope to those who believe that transparency and corporate success can mix. Back in 2009, scientists working for a Swedish biotech firm called WntResearch published a proof-of-principle paper about their key molecule. Called Foxy-5, the molecule appeared to help the drug tamoxifen suppress tumor cells, thereby preventing the spread of cancer.
The Proceedings of the National Academy of Sciences (PNAS) lifted the embargo early Friday on a paper, after a news outlet broke it three days before it was scheduled to lift. From an email sent to the journal’s media list Friday:PNAS is lifting the embargo on the following manuscript. All other manuscripts are under the scheduled embargo of Monday, May 22, 3 pm US ET. Researchers report that female mentors early in college might influence the retention rate of women in engineering programs.